[Top] [All Lists]

[e-drug] Independent Drug & Healthcare Newsletter for June 2016

E-DRUG: Independent Drug & Healthcare Newsletter for June 2016

Newsletter, June 2016

If your friends or colleagues would be interested, forward this email and 
invite them to sign up for the free Newsletter.

N° 172 June 2016
> View the table of contents for the current issue

Subscribe to Prescrire International

In Prescrire's Spotlight this month

Empagliflozin (Jardiance°) in type 2 diabetes: no rush to use this drug

FEATURED REVIEW  There is no evidence that empagliflozin has a favourable 
harm-benefit balance when used for prevention of the cardiovascular 
complications of type 2 diabetes. More trial data are needed on the 
harm-benefit balance of empagliflozin compared to other cardiovascular 
Full review (3 pages) available for download by subscribers.
> Read more

In the June issue of Prescrire International: decongestants during pregnancy - 
risks for the unborn child
FREE DOWNLOAD  Sympathomimetic decongestants provoke serious, albeit rare, 
adverse effects. In the second and third trimesters of pregnancy, the fetus is 
exposed to the same adverse effects as the mother. These drugs should quite 
simply never be used, including via the nasal route. 
Full text available for free download.
> Read more

Prescrire: 100% financed by subcribers
Prescrire, financed solely through subscriptions, with no revenues from 
advertising or grants, publishes its accounts each year.
> Read more

2015 drug packaging review: drug companies and insufficient regulation are 
putting patients at risk
Pharmaceutical companies are fully aware of the solutions for ensuring the 
quality and safety of drug packaging. But too much drug packaging remains 
unsafe and too many package leaflets are inadequate.
> Read more

The drug pricing racket
The extortionate prices of some new drugs supposedly reflect their "value" for 
patients and for society. This argument does not hold water.
> Read more

Remembering Andrew Herxheimer
A long-time friend and colleague and a source of inspiration for Prescrire, 
Andrew Herxheimer passed away on 21 February 2016 at the age of 90. Prescrire 
was greatly enriched by Andrew's ideas, vision, enthusiasm and experience.
> Read more

Share this with a friend or colleague: Forward this email
Get this from a friend? Sign up here

"Prescrire International" <international@prescrire.org>

<Prev in Thread] Current Thread [Next in Thread>
  • [e-drug] Independent Drug & Healthcare Newsletter for June 2016, Prescrire International <=